Vaccinex IncNASDAQ:VCNXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE3.6800
- TODAY'S CHANGE (%)-0.0100 (-0.2710%)
- Bid / Lots3.6400/ 5
- Ask / Lots3.8200/ 6
- Open / Previous Close3.6100 / 3.6900
- Day Range
- 52 Week Range
- Volume18,844
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VCNX |
|---|---|---|
| 09:32 ET | 215 | 3.61 |
| 10:11 ET | 1000 | 3.734 |
| 10:33 ET | 100 | 3.8299 |
| 10:42 ET | 100 | 3.82 |
| 10:49 ET | 200 | 3.8199 |
| 10:54 ET | 100 | 3.73 |
| 10:58 ET | 100 | 3.73 |
| 11:25 ET | 600 | 3.7 |
| 11:34 ET | 401 | 3.81 |
| 11:39 ET | 100 | 3.7 |
| 11:52 ET | 200 | 3.69 |
| 12:15 ET | 100 | 3.67 |
| 12:19 ET | 100 | 3.68 |
| 12:21 ET | 900 | 3.68 |
Nov 18, 2024
Press Release: Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 8:30AM ET on Monday Nov 18, 2024 by Dow Jones
8:30AM ET on Monday Nov 18, 2024 by Dow JonesVaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 8:30AM ET on Monday Nov 18, 2024 by Dow Jones
8:30AM ET on Monday Nov 18, 2024 by Dow Jones
Nov 7, 2024
Vaccinex Provides Update on ActivMAb(R) Platform: Multiple Project Deals and Presentation at SITC, from 8:30AM ET on Thursday Nov 07, 2024 by Dow Jones
8:30AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 5, 2024
Oct 31, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Vaccinex Inc | 9.9M | -0.3x | --- |
Yubo International Biotech Ltd | 9.7M | -5.1x | --- |
BioCardia Inc | 10.8M | -0.5x | --- |
BioRestorative Therapies Inc | 10.2M | -2.1x | --- |
Soligenix Inc | 8.3M | -0.4x | --- |
Brainstorm Cell Therapeutics Inc | 9.9M | -0.5x | --- |
Company Information
Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimer’s disease, head and neck, pancreatic and breast cancer. Its lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including cancer. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.
Contact Information
- Headquarters
- 1895 Mount Hope AveROCHESTER, NY, United States 14620-4540
- Phone
- 585-271-2700
- Fax
- 585-271-2765
Executives
- Chairman of the Board
- Albert Friedberg
- President, Chief Executive Officer, Director
- Maurice Zauderer
- Interim Chief Financial Officer
- Jill Sanchez
- Chief Operating Officer, Senior Vice President - Discovery and Translational Medicine
- Elizabeth Evans
- Senior Vice President - Research, Chief Scientific Officer
- Ernest Smith
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $9.9M |
|---|---|
Revenue (TTM) | $388.0K |
Shares Outstanding | 2.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.08 |
EPS | $-12.15 |
Book Value | $-2.59 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 25.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -5,241.24% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
